Thomas M. Ashton
Oxford, ENG OX37DQ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.
Journal: RSC medicinal chemistry
Published: August 24, 2025
Synthesis of cerium, zirconium, and copper doped zinc oxide nanoparticles as potential biomaterials for tissue engineering applications.
Journal: Heliyon
Published: November 06, 2023
Global fine-resolution data on springtail abundance and community structure.
Journal: Scientific data
Published: August 07, 2023
Enhancing bifunctional catalytic activity of cobalt-nickel sulfide spinel nanocatalysts through transition metal doping and its application in secondary zinc-air batteries.
Journal: RSC advances
Published: September 30, 2020
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Journal: Cell death & disease
Published: August 03, 2018
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 17, 2017
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Journal: British journal of cancer
Published: May 10, 2017
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.
Journal: Nature communications
Published: December 04, 2015
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: September 11, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026